<DOC>
	<DOCNO>NCT02586363</DOCNO>
	<brief_summary>In clinical trial , investigator clarify difference pharmacokinetics group single dose Cavir Tab . 0.5mg single dose Cavir Tab . 0.5mg high fatty meal healthy adult volunteer . The investigator evaluate effect food intake absorption Cavir Tab . 0.5mg .</brief_summary>
	<brief_title>Study Evaluation Cavir Tab . 0.5mg With Food Effect Pharmacokinetics Safety</brief_title>
	<detailed_description />
	<mesh_term>Entecavir</mesh_term>
	<criteria>Healthy male , age 19 ~ 45 screen date Subject ` weight range 120 percentage +120 percentage ideal body weight calculate { height ( cm ) 100 } * 0.9 . The Subject willing able provide write informed consent participate study Subject history clinically significant disease . Subject digestive disease ( Crohn ` disease , ulcer , acute chronic pancreatitis etc ) abdomen surgery ( exclude , simple appendectomy hernia operation ) . Subject hypersensitivity history clinically significance additive . Subject inappropriate screening ( disease history , physical examination , vital sings , electrocardiogram , laboratory test etc . ) Subject laboratory test result indicate one follow . serum aspartate aminotransferase &gt; 1.25 * normal limit serum Total bilirubin &gt; 1.5 * normal upper limit serum CPK &gt; 1.5 * normal upper limit eGFR ( estimate Glomerular Filtration Rate ) calaulated MDRD ( Modification Diet Renal Disease ) formula &lt; 60 mL/min/1.73m2 Subject hypertension ( SBP &gt; 140mmHg DBP &gt; 90mmHg ) hypotension ( SBP &lt; 90mmHg , DBP &lt; 60mmHg ) Subject drug abuse history . Subject currently abuse alcohol ( 210 g/week ) , caffeine ( 5cups/day ) smoking ( half pack ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Entecavir</keyword>
	<keyword>Food effect</keyword>
	<keyword>Cavir Tab 0.5mg</keyword>
	<keyword>Baraclude Tab . 0.5mg</keyword>
</DOC>